

A phase 1, single-center, double-blind study of AM103 in healthy volunteers

Submission date 08/06/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 09/08/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 29/10/2021	Condition category Signs and Symptoms	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Sjoerd van Marle

Contact details
Stationsweg 163
9470 AE Zuidlaren
Netherlands
9470 AE

Additional identifiers

EudraCT/CTIS number
2007-002229-59

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
The Sponsor (Amira) code: CL-AM103-01; PRA International (a contract research organization) code: AMA70921-070921

Study information

Scientific Title

A phase 1, single-center, double-blind study of AM103 in healthy volunteers

Study objectives

To assess the following:

Primary:

Safety and tolerability of single and multiple doses of AM103 following oral administration.

Secondary:

1. Pharmacokinetics (PK) of AM103 after single and multiple doses.
2. Effects of AM103 on Pharmacodynamic (PD) markers: whole blood ionophore-stimulated leukotriene LTB4 and urinary LTE4 production.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Medical Ethical Review Committee (METC) of the BEBO foundation (Ethics Review / Bio-medical Research) (METC van de stichting BEBO) Postbus 1004, 9400 BA Assen, and Noorderstaete 20, 9402 XB Assen, the Netherlands. Approved on 22nd May 2007.

Study design

Single-center, double-blind, randomized, placebo-controlled, single dose followed by multiple dose study.

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet**Health condition(s) or problem(s) studied**

Healthy volunteers. Study is primarily relevant in asthma and allergic rhinitis.

Interventions

AM103 orally or placebo

Single doses: 50, 150, 300, 600, 1000 mg

Multiple doses: Administered once daily for 11 days. The doses are: 150, 300 and 600 mg, with an additional group to be defined (after the prior doses have concluded).

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

1. Adverse events
2. Physical examinations
3. Vital signs
4. ECGs
5. Clinical laboratory values

Single Dose Study: Physical examination, vital signs, ECG, and clinical laboratory tests will be carried out on Day 4 (72 ± 4 hours, end-of study time point) after study drug administration.

Multiple Dose Study:

Vital signs will be assessed at the following timepoints:

Day 1: pre-dose, 1, 2, 4, 12, and 24 hours after study drug administration

Days 2-10: pre-dose, 2 and 12 hours after study drug administration

Day 11: pre-dose, 2, 12 and 24 hours after study drug administration

Physical examination, vital signs, ECG, and clinical laboratory tests will be carried out on Day 14 (72 ± 4 hours after the Day 11 dose).

ECGs will be carried out at the following timepoints:

Single Dose Phase: 2-4 hours after the study drug administration

Multiple Dose Phase: 2-4 hours after the first dose of study drug on Day 1 and 2-4 hours after study drug administration on Days 5 and 11.

Secondary outcome measures

1. Pharmacokinetics: Concentrations of AM103 in plasma samples will be determined by validated Liquid Chromatography/Mass Spectrometry (LCMS) methods.
2. Pharmacodynamics: Whole blood ionophore-stimulated leukotriene LTB₄ and urinary LTE₄ production to be assayed by Enzyme Linked Immunosorbent Assay (ELISA) and mass spectrometry, respectively.

Overall study start date

18/06/2007

Completion date

31/10/2007

Eligibility

Key inclusion criteria

1. Male or female between 18 and 65 years of age (for Multiple Dose Phase, male only)
2. Female subjects must be postmenopausal, surgically sterile, or be prepared to use two methods of contraceptives during the study and for 14 days after the end of dosing
3. Non-smoker
4. Good general health as determined by medical history, and by results of physical examination, vital signs, Electrocardiogram (ECG), and clinical laboratory tests obtained within 21 days (3

weeks) prior to study drug administration

5. Able to provide written informed consent and understand and comply with the requirements of the study

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Up to 72 (40 in single dose phase; 32 in multiple dose phase)

Total final enrolment

86

Key exclusion criteria

1. Prior exposure to AM103 (no subject may participate in more than one cohort)
2. History or presence of any significant organ system disease, including phenylketonuria, as assessed by medical history, physical examination and laboratory evaluation
3. 12-lead ECG with any abnormality judged by the Investigator to be clinically significant or QTc interval of >450 milliseconds
4. Presence or history of any abnormality or illness, which in the opinion of the Investigator may affect absorption, distribution, metabolism or elimination of the study drug
5. Any screening laboratory evaluation outside the laboratory reference range that is judged by the Investigator to be clinically significant
6. Hemoglobin <7 mmol/L
7. Positive serum test for HIV, hepatitis C or hepatitis B virus infection
8. History of significant allergy to any medication
9. History of alcohol or drug abuse within the past 24 months or positive urine drug screen during screening
10. Use of any tobacco or nicotine containing product within the previous 6 months
11. Administration of any prescription drug within 21 days (oral contraceptives permitted) or over-the-counter drug (paracetamol and ibuprofen ≤ 1 g/day permitted) or herbal supplement within 7 days of study drug administration
12. Administration or use of any investigational drug or device within 30 days of study drug administration
13. Blood or plasma donation within 60 days prior to dosing

Date of first enrolment

18/06/2007

Date of final enrolment

31/10/2007

Locations

Countries of recruitment

Netherlands

Study participating centre

Stationsweg 163

9470 AE Zuidlaren

Netherlands

9470 AE

Sponsor information

Organisation

Amira Pharmaceuticals (USA)

Sponsor details

c/o Dr Mark Moran

9535 Waples Street, Ste. 100

San Diego

United States of America

92121

Sponsor type

Industry

Website

<http://www.amirapharm.com/>

ROR

<https://ror.org/00gtmwv55>

Funder(s)

Funder type

Industry

Funder Name

Amira Pharmaceuticals (USA)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		24/02/2010	29/10/2021	Yes	No